Answers are grounded in this paper and cite their sources.
Approximately 34 920 people in the US and 155 688 people worldwide are diagnosed with multiple myeloma each year. Induction therapy with an injectable proteasome inhibitor, an oral immunomodulatory agent and dexamethasone followed by treatment with autologous hematopoietic stem cell transplantation, and maintenance therapy with lenalidomide are among the treatments considered standard care for eligible patients.
No takes yet. Share an insight, caveat, or question.
Cowan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: